medigraphic.com
ISSN 0188-9796 (Print)

2011, Number 3

<< Back Next >>

Rev Endocrinol Nutr 2011; 19 (3)

Analysis of quality of life in patients with acromegaly at Centro Médico Nacional 20 de Noviembre, ISSSTE

Garduño-Pérez ÁA, Zamarripa-Escobedo R, Vergara-López A, Guillén-González MÁ, Escudero-Licona I

Language: Spanish
References: 14
Page: 97-101
PDF size: 74.22 Kb.


ABSTRACT

Background: Acromegaly is a disease that impairs quality of life. Our objective was to evaluate the quality of life of patients with acromegaly at the CMN 20 de Noviembre. Materials and methods: We included 50 patients with pituitary GH-producing adenomas, aged 18 to 70 years, in whom the AcroQoL questionnaire was applied. We analyzed gender, disease activity (GH and IGF1 levels), tumor size, number of co-morbidities, and type of treatment. These parameters were correlated with the different AcroQoL scores. Results: The average score obtained by our patients was lower than the AcroQoL controls reflecting a lower quality of life. When analyzed by gender, women had a lower score (49.60 ± 21.59 vs 57.85 ± 13.63 p = 0.027) and patients with higher number of comorbidities had a worse quality of life (p = 0.001). No association was found between the levels of GH with octreotide treatment and criteria of cure. Conclusions: Quality of life of this group of patients with acromegaly at our hospital is lower than the reported by the AcroQoL group; women have a greater deterioration in quality of life.


REFERENCES

  1. Guyatt GH, CooK DJ. Health status, quality of life, and the individual. JAMA 1994; 272: 630-631.

  2. Testa MA, Simonson DC. Assessment of quality of life outcomes. N Engl J Med 1996; 334: 835-840.

  3. Bradley C. Importance of differentiating health. Lancet 2001; 357: 7-8.

  4. Velarde-Jurado E, Ávila-Figueroa C. Evaluación de la calidad de vida. Salud Publica Mex 2002; 44: 349-361.

  5. Zúñiga MA, Carrillo-Jiménez GT. Evaluación del estado de salud con la encuesta SF-36L resultados preliminares en México. Salud Publica Mex 1999; 41: 110-118.

  6. Badia X, Webb S, Prieto L, Lara N. Acromegaly quality of life questionnaire (AcroQoL). Health Qual Life Outcomes 2004; 2: 13.

  7. Webb SM, Prieto L, Badia X, Albareda M, Catalá M, Gaztambide S et al. Acromegaly quality of life questionnaire (AcroQoL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol 2002; 57: 251-258.

  8. Webb SM, Badia X, Lara N. Spanish AcroQoL study group. Validity and clinical applicability of the acromegaly quality questionnarire, AcroQoL: a 6 month prospective study. Eur J Endocrinol 2006; 155: 269-277.

  9. Webb SM. Quality of life in acromegaly. Neuroendocrinology 2006; 83: 224-229.

  10. Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM, Christ ER. Assessment of quality of life in patients with uncontrolled vs controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clin Endocrinol 2005; 63: 103-110.

  11. Biermasz N, Pereira A et al. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005; 90: 2731-2739.

  12. Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JWA, Romijn JA, Roelfsema F. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 2004; 89: 5369-5376.

  13. Melmed S, Casanueva P. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005; 153: 737-740.

  14. Melmed S. Acromegaly. N Engl J Med 2006; 355: 2558-2573.




2020     |     www.medigraphic.com